The CIOMS/RUCAM scale, while clinically useful, has significant limitations ( Table 7 )
modulating refers to altering the expression of a target polynucleotide or polypeptide
Semaglutide is a single-action GLP-1 agonist with an average weight reduction of 12 to 15 percent in clinical trials (over 68 weeks)
Adding glutathione to a base IV incurs $30-$100 additional cost per treatment
the antibody or ADC comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 12G3H11, B233, B208, B210, G5, 10C12, 4H5, 10G9, 3F2, 1C1, 1F12, 1H3, 1D3, 2B12, or 5A8
2 Materials and methods 2.1 Search strategy A systematic literature search was performed using the PubMed, Web of Science, Embase, and Cochrane databases, as well as the China National Knowledge Infrastructure (CNKI) in December 2023 using the following search terms: (Hashimoto Disease[MeSH Terms]) OR (Disease, Hashimoto[Other Term]) OR (Chronic Lymphocytic Thyroiditis[Other Term]) OR (Chronic Lymphocytic Thyroiditides[Other Term]) OR (Lymphocytic Thyroiditides, Chronic[Other Term]) OR (Lymphocytic Thyroiditis, Chronic[Other Term]) OR (Thyroiditides, Chronic Lymphocytic[Other Term]) OR (Thyroiditis, Chronic Lymphocytic[Other Term]) OR (Hashimoto Struma[Other Term]) OR (Hashimotos Struma[Other Term]) OR (Hashimotos Syndrome[Other Term]) OR (Hashimoto Syndrome[Other Term]) OR (Hashimotos Syndromes[Other Term]) OR (Hashimotos Syndrome[Other Term]) OR (Syndrome, Hashimotos[Other Term]) OR (Syndromes, Hashimotos[Other Term]) OR (Hashimotos Disease[Other Term]) OR (Disease, Hashimotos[Other Term]) OR (Hashimotos Disease[Other Term]) OR (Hashimoto Thyroiditis[Other Term]) OR (Hashimoto Thyroiditides[Other Term]) OR (Thyroiditides, Hashimoto[Other Term]) OR (Thyroiditis, Hashimoto[Other Term]) AND (selenium[MeSH Terms]) OR (Vitamin d[MeSH Terms]) OR (Myo-inositol[MeSH Terms])
